Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin.

Falkson CI, Falkson HC, Falkson G

Oncology1 Jul 1996Cited by 9 (Europe PMC)

PMID8692536DOI10.1159/000227579PepBankPUB-08692536

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In ovarian cancer, objective response occurred in 12 of 18 patients with added decapeptyl versus 9 of 14 with cisplatin alone.
In plain wordsIn ovarian cancer, responses occurred in 12 of 18 patients with added decapeptyl versus 9 of 14 with cisplatin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedObjective response
Study
n = 32
Comparator
Cisplatin alone
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Objective response
9 patients (of 14)
cisplatin alone
Objective response
12 patients (of 18)
cisplatin plus decapeptyl
Source sentences
Summary
Objective response (complete and partial response) was documented in 9 of 14 patients on cisplatin and in 12 of 18 patients on cisplatin plus decapeptyl.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with histologically confirmed ovarian cancer were entered into a pilot study.
Summary · context
Patients were randomized to receive cisplatin alone or cisplatin plus D-Trp-6-LHRH(decapeptyl).
Report a problemFND-0869253601
02HumanRandomized controlled trialEfficacy outcome
In ovarian cancer, median time to treatment failure was the same with added decapeptyl and cisplatin alone.
In plain wordsIn ovarian cancer, time to treatment failure was the same with added decapeptyl and cisplatin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTime to treatment failure
Study
n: not reported in source
Comparator
Cisplatin alone
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Median time to treatment failure and median survival times were the same in the two treatment regimens.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with histologically confirmed ovarian cancer were entered into a pilot study.
Summary · context
Patients were randomized to receive cisplatin alone or cisplatin plus D-Trp-6-LHRH(decapeptyl).
Report a problemFND-0869253602
03HumanRandomized controlled trialEfficacy outcome
In ovarian cancer, median survival was the same with added decapeptyl and cisplatin alone.
In plain wordsIn ovarian cancer, median survival was the same with added decapeptyl and cisplatin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeSurvival
Study
n: not reported in source
Comparator
Cisplatin alone
Outcome group
Mortality · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Median time to treatment failure and median survival times were the same in the two treatment regimens.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with histologically confirmed ovarian cancer were entered into a pilot study.
Summary · context
Patients were randomized to receive cisplatin alone or cisplatin plus D-Trp-6-LHRH(decapeptyl).
Report a problemFND-0869253603
04HumanRandomized controlled trialSafety outcome
In ovarian cancer, toxicities were similar with added decapeptyl and cisplatin alone, except for hot flashes.
In plain wordsIn ovarian cancer, toxicities were similar with added decapeptyl and cisplatin alone, except for hot flashes.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeToxicities
Study
n: not reported in source
Comparator
Cisplatin alone
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Toxicities were similar in the two treatment arms, except for hot flashes which only occurred in patients on cisplatin plus decapeptyl.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with histologically confirmed ovarian cancer were entered into a pilot study.
Summary · context
Patients were randomized to receive cisplatin alone or cisplatin plus D-Trp-6-LHRH(decapeptyl).
Report a problemFND-0869253604
05HumanRandomized controlled trialSafety outcome
In ovarian cancer, hot flashes occurred only with cisplatin plus decapeptyl.
In plain wordsIn ovarian cancer, hot flashes occurred with added decapeptyl but not with cisplatin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseHot flashes
Study
n: not reported in source
Comparator
Cisplatin alone
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Toxicities were similar in the two treatment arms, except for hot flashes which only occurred in patients on cisplatin plus decapeptyl.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with histologically confirmed ovarian cancer were entered into a pilot study.
Summary · context
Patients were randomized to receive cisplatin alone or cisplatin plus D-Trp-6-LHRH(decapeptyl).
Report a problemFND-0869253605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.